Adesanya, A. v. Novartis Pharmaceuticals Corp.

CourtSuperior Court of Pennsylvania
DecidedSeptember 18, 2018
Docket830 EDA 2018
StatusUnpublished

This text of Adesanya, A. v. Novartis Pharmaceuticals Corp. (Adesanya, A. v. Novartis Pharmaceuticals Corp.) is published on Counsel Stack Legal Research, covering Superior Court of Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Adesanya, A. v. Novartis Pharmaceuticals Corp., (Pa. Ct. App. 2018).

Opinion

J-S48032-18

NON-PRECEDENTIAL DECISION - SEE SUPERIOR COURT I.O.P. 65.37

AFOLUSO ADESANYA AND : IN THE SUPERIOR COURT OF ADENEKAN HEZEKIAH ADESANYA : PENNSYLVANIA : Appellants : : v. : : NOVARTIS PHARMACEUTICALS : CORPORATION : No. 830 EDA 2018 : Appellee :

Appeal from the Order Entered February 12, 2018 in the Court of Common Pleas of Montgomery County Civil Division at No.: 2017-25091

BEFORE: DUBOW, J., MURRAY, J., and PLATT*, J.

MEMORANDUM BY PLATT, J.: FILED SEPTEMBER 18, 2018

Appellants, Afoluso Adesanya and Adenekan Hezekiah Adesanya, wife

and husband respectively, appeal pro se from the order denying their “Joint

and Consolidated Petition to Strike Entry of Foreign Judgment and for

Protection Order.” We affirm on the basis of the trial court opinion.

The trial court aptly summarizes the factual and procedural history of

the case. Therefore, we need not repeat them at length here. For the

convenience of the reader, we note briefly that Appellants appeal from the

order denying their petition to strike a foreign judgment in favor of Appellee,

Novartis Pharmaceuticals Corporation, which was transferred from New Jersey

____________________________________ * Retired Senior Judge assigned to the Superior Court. J-S48032-18

pursuant to the Uniform Enforcement of Foreign Judgments Act (UEFJA), 42

Pa.C.S.A. § 4306.1

Our review of the record before us reflects that the suit underlying the

foreign judgment stemmed from an employment dispute. Briefly summarized,

Appellee claimed that Afoluso obtained employment by use of a fraudulent

résumé, accepted relocation expenses to move from Pennsylvania to New

Jersey, but did not in fact relocate, and while supposedly working full time for

Appellee out of her home, developed and operated a consulting business which

included rendering services to competitors of Appellee. Afoluso was

eventually terminated over performance issues.

Afoluso sued. The New Jersey district court granted summary judgment

in favor of Appellee.2 Appellee transferred the district court judgments to the

Montgomery County Court of Common Pleas. The trial court denied

Appellants’ petitions to strike the judgments. This timely appeal followed.

The trial court did not order a statement of errors. See Pa.R.A.P. 1925(b).

Appellants present three over-lapping questions for our review, which

we reproduce verbatim:

a. The review of entry of Foreign Judgment is a technical review;

____________________________________________

1 See Pa.R.A.P. 311(a)(1) (providing for interlocutory appeal as of right for order refusing to strike off judgment).

2 Both briefs represent that the federal case is pending appeal in the Third Circuit. (See Appellants’ Brief, at 8; Appellee’s Brief, at 4).

-2- J-S48032-18

i. Did the Trial Court err as a matter of Law by not giving Full review on the technical requirements per statute governing the entry of foreign judgment in Pennsylvania? (See 42 Pa. C.S. § 4306(b))

b. Did the Trial Court abuse its discretion by overlooking the fatal errors on face of record at entry?

c. Did the Trial Court abuse its discretion by ignoring its own findings of severe violations by Novartis and other infarctions (sic) during the proceedings prior to and after final rule but before Opinion was issued?

(Appellants’ Brief, at 7).

Our standard of review from the denial of a petition to strike a judgment is limited to whether the trial court manifestly abused its discretion or committed an error of law. The full faith and credit clause of the United States Constitution requires state courts to recognize and enforce the judgments of sister states. U.S. Const. Art. 4, § 1.

Reco Equip., Inc. v. John T. Subrick Contracting, Inc., 780 A.2d 684, 686

(Pa. Super. 2001), appeal denied, 790 A.2d 1018 (Pa. 2001) (citation

omitted). “As with all questions of law, the appellate standard of review is de

novo and the appellate scope of review is plenary.” Olympus Corp. v.

Canady, 962 A.2d 671, 673 (Pa. Super. 2008) (citation omitted).

Appellants’ questions all implicate the entry of the foreign judgment,

based on the allegation of technical errors. We review them together.

After a thorough review of the record, the briefs of the parties, the

applicable law, and the well-reasoned opinion of the Honorable Gary S. Silow,

we conclude that Appellants’ issues merit no relief. The trial court opinion

comprehensively discusses and properly disposes of the questions presented.

-3- J-S48032-18

(See Trial Court Opinion, 4/27/18, at 2-4) (concluding that Appellee

submitted a properly certified and authenticated copy of the district court’s

judgment, and docket, in compliance with UEFJA, 42 Pa.C.S.A. § 4306

(enforcement of foreign judgments) and 42 Pa.C.S.A. § 5328 (proof of official

records)).

Accordingly, we affirm on the basis of the trial court’s opinion.

Order affirmed.

Judgment Entered.

Joseph D. Seletyn, Esq. Prothonotary

Date: 9/18/18

-4- 2017-25091-0058 Opinion, Circulated 08/29/2018 Page 01:00 PM 1

IN THE COURT OF COMMON PLEAS OF MONTGOMERY COUNTY, PENNSYLVANIA CIVIL DIVISION

AFOLUSO ADESANYA and NO. 17-25091 ADENEKAN HEZEKIAH ADESANY A Plaintiffs

v. 111 ����.DI\ I 2017-25091-0058 412712018 2:40 PM # 11755191 NOVARTIS PHARMACEUTICALS Rcpt#Z3382417 Fee:$0.00 Opinion Main (Public) CORPORATION Mon\Co Prolhonolal'{ Defendant

OPINION

SILOW, J. APRIL Z 1 , 2018 Afoluso Adesanya and Adenekan Hezekiah Adesanya ("petitioners")

appeal prose from the Order dated February 9, 2018,1 which denied their

"Joint and Consolidated Petition to Strike Entry of Foreign Judgment and for

Protection Order." For the reasons set forth below, the Order should be

affirmed.

I. FACTUAL BACKGROUND AND PROCEDURAL HISTORY

Afoluso Adesanya sued Novartis Pharmaceuticals Corporation

("Novartis") in U.S. District Court for the District of New Jersey. Novartis

counterclaimed. The District Court ultimately entered judgment against

Afoluso Adesanya on her claims and certain of Novartis' counterclaims and

entered a judgment in favor of Novartis against Adenekan Hezekiah Adesanya,

the husband of Afoluso Adesanya.

I The Order was docketed on February 12, 2018. 2017-25091-0058 Opinion, Page 2

Novartis subsequently transferred the District Court judgments to this

court. Petitioners, appearing prose, filed the instant "Joint and Consolidated

Petition to Strike Entry of Foreign Judgment and for Protection Order" on

November 6, 2017. Novartis opposed the Petition and this court denied relief

by Order dated February 9, 2018. Petitioners filed a timely notice of appeal.2

II. DISCUSSION

1. This court properly denied the Petition to Strike Entry of Foreign Judgment and for Protection Order.

Petitioners asserted in support of their Petition that a fatal defect exists

because the foreign judgment documents were not authenticated pursuant to

42 Pa. C.S. § 4306 and 28 U.S.C. § 1738.3 They further contended that the

documents filed by Novartis in this court contain a fatal defect because they

Free access — add to your briefcase to read the full text and ask questions with AI

Related

RECO Equipment, Inc. v. John T. Subrick Contracting, Inc.
780 A.2d 684 (Superior Court of Pennsylvania, 2001)
Olympus Corp. v. Canady
962 A.2d 671 (Superior Court of Pennsylvania, 2008)
Medina & Medina, Inc. v. Gurrentz International Corp.
450 A.2d 108 (Superior Court of Pennsylvania, 1982)

Cite This Page — Counsel Stack

Bluebook (online)
Adesanya, A. v. Novartis Pharmaceuticals Corp., Counsel Stack Legal Research, https://law.counselstack.com/opinion/adesanya-a-v-novartis-pharmaceuticals-corp-pasuperct-2018.